Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
- 10 December 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (23) , 4136-4146
Abstract
Key Points: In adults undergoing allo-HSCT, vedolizumab IV 300 mg was well tolerated and had a low incidence of overall and lower-intestinal aGVHD. These phase 1b data support further evaluation of vedolizumab for the prevention of aGVHD in adults undergoing allo-HSCT.Keywords
This publication has 35 references indexed in Scilit:
- Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortalityBlood, 2013
- What predicts high risk acute graft‐versus‐host disease (GVHD) at onset?: identification of those at highest risk by a novel acuteGVHDrisk scoreBritish Journal of Haematology, 2012
- Risk factors for acute GVHD and survival after hematopoietic cell transplantationBlood, 2012
- Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host diseaseBlood, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effectsJournal of Leukocyte Biology, 2006
- Absence of β7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestineBlood, 2006
- MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1Nature, 1993
- On Simultaneous Confidence Intervals for Multinomial ProportionsTechnometrics, 1965